JM Financial Q4 net profit at Rs 114 cr

JM Financial Q4 net profit at Rs 114 cr

FPJ BureauUpdated: Friday, May 31, 2019, 03:26 PM IST
article-image

Mumbai:  Financial services firm JM Financial reported a 22 % rise in net profit at Rs 113.74 crore for the March quarter, backed by steady performance of its fund-based and asset management businesses.    However, the Rs 113.74 crore profit registered in the fourth quarter is nearly 3 % lower than the profit of Rs 117 crore reported in the preceding December quarter.  “Looking at the performance for the full year, the fund-based businesses and asset management business have done reasonably well,” JM Financial Group Chairman Nimesh Kampani said. “It reflects our ongoing strategy to build platforms for growth while continuing focus on maintaining leadership in the advisory business,” he said. According to Kampani, “The company would additionally focus to leverage on evolving opportunities in technology-backed platforms that can be complementary to our businesses, during the current fiscal.”  JM Financial’s consolidated revenue rose 21 % to Rs 474.55 crore during the fourth quarter.

RECENT STORIES

Gold Tumbles ₹700 To ₹98,420/10g, Strong US Dollar & Fed Rate Worries Weigh

Gold Tumbles ₹700 To ₹98,420/10g, Strong US Dollar & Fed Rate Worries Weigh

Adani Enterprises ₹1,000 Crore Bond Issue Fully Subscribed, Investors Respond In Just Three Hours

Adani Enterprises ₹1,000 Crore Bond Issue Fully Subscribed, Investors Respond In Just Three Hours

Centre Tells Delhi High Court There's No Proposal To Issue ₹50 Coin Amid Plea Over Note's...

Centre Tells Delhi High Court There's No Proposal To Issue ₹50 Coin Amid Plea Over Note's...

Sensex, Nifty End Lower As IT & Oil Stocks Drag, Caution Builds Ahead Of Q1 Earnings Season

Sensex, Nifty End Lower As IT & Oil Stocks Drag, Caution Builds Ahead Of Q1 Earnings Season

Lupin, Zentiva Sign Global Pact For Certolizumab Pegol, Biosimilar To Be Commercialised Across Key...

Lupin, Zentiva Sign Global Pact For Certolizumab Pegol, Biosimilar To Be Commercialised Across Key...